Tumor response from durvalumab (MEDI4736) + tremelimumab treatment in patients with advanced non-small cell lung cancer (NSCLC) is observed regardless of PD-L1 status

Rizvi, N., Chaft, J., Balmanoukian, A., Goldberg, S. B., Sanborn, R. E., Steele, K. E., … Antonia, S. (2015). Tumor response from durvalumab (MEDI4736) + tremelimumab treatment in patients with advanced non-small cell lung cancer (NSCLC) is observed regardless of PD-L1 status. Journal for ImmunoTherapy of Cancer, 3(S2). https://doi.org/10.1186/2051-1426-3-s2-p193